A systematic review published by Priesterroth et al. [12] reported findings on the associations between diabetes technology and diabetes-specific eating disorders in T1DM, suggesting that the increased flexibility of insulin administration with CSII may offer clinical benefits in diabetes-specific eating disorders. The gene discussed is INS; the disease is eating disorder.